Seetharama Jois - Search Results

Year	Number of Results
2000	1
2002	2
2003	5
2004	4
2005	3
2006	3
2007	1
2008	1
2014	1
2015	6
2016	5
2017	6
2018	6
2019	3
2020	11
2021	10
2022	8
2023	3
2024	0

1

EGFR trafficking: effect of dimerization, dynamics, and mutation.

Schultz DF, Billadeau DD, Jois SD. Schultz DF, et al. Among authors: jois sd. Front Oncol. 2023 Sep 11;13:1258371. doi: 10.3389/fonc.2023.1258371. eCollection 2023. Front Oncol. 2023. PMID: 37752992 Free PMC article. Review.

2

Peptides and peptidomimetics as therapeutic agents for Covid-19.

Dahal A, Sonju JJ, Kousoulas KG, Jois SD. Dahal A, et al. Among authors: jois sd. Pept Sci (Hoboken). 2022 Jan;114(1):e24245. doi: 10.1002/pep2.24245. Epub 2021 Oct 11. Pept Sci (Hoboken). 2022. PMID: 34901700 Free PMC article. Review.

3

Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment.

Sonju JJ, Dahal A, Singh SS, Jois SD. Sonju JJ, et al. Among authors: jois sd. J Control Release. 2021 Jan 10;329:624-644. doi: 10.1016/j.jconrel.2020.09.055. Epub 2020 Oct 1. J Control Release. 2021. PMID: 33010333 Free PMC article. Review.

4

Design of beta-turn based therapeutic agents.

Kee KS, Jois SD. Kee KS, et al. Among authors: jois sd. Curr Pharm Des. 2003;9(15):1209-24. doi: 10.2174/1381612033454900. Curr Pharm Des. 2003. PMID: 12769748 Review.

5

Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer.

Pallerla S, Abdul AURM, Comeau J, Jois S. Pallerla S, et al. Among authors: jois s. Int J Mol Sci. 2021 Jan 14;22(2):779. doi: 10.3390/ijms22020779. Int J Mol Sci. 2021. PMID: 33466691 Free PMC article. Review.

6

Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design.

Singh SS, Jois SD. Singh SS, et al. Among authors: jois sd. Adv Protein Chem Struct Biol. 2018;111:1-59. doi: 10.1016/bs.apcsb.2017.08.003. Epub 2017 Oct 6. Adv Protein Chem Struct Biol. 2018. PMID: 29459028 Free PMC article. Review.

7

Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy.

Singh SS, Dahal A, Shrestha L, Jois SD. Singh SS, et al. Among authors: jois sd. Curr Med Chem. 2020;27(32):5274-5316. doi: 10.2174/0929867326666190222183219. Curr Med Chem. 2020. PMID: 30854949 Review.

8

Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR).

Kaufman NEM, Dhingra S, Jois SD, Vicente MDGH. Kaufman NEM, et al. Among authors: jois sd. Molecules. 2021 Feb 18;26(4):1076. doi: 10.3390/molecules26041076. Molecules. 2021. PMID: 33670650 Free PMC article. Review.

9

Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors.

Kanthala S, Pallerla S, Jois S. Kanthala S, et al. Among authors: jois s. Future Oncol. 2015;11(5):865-78. doi: 10.2217/fon.14.312. Future Oncol. 2015. PMID: 25757687 Free PMC article. Review.

10

GHRH antagonists support lung endothelial barrier function.

Uddin MA, Akhter MS, Singh SS, Kubra KT, Schally AV, Jois S, Barabutis N. Uddin MA, et al. Among authors: jois s. Tissue Barriers. 2019;7(4):1669989. doi: 10.1080/21688370.2019.1669989. Epub 2019 Oct 3. Tissue Barriers. 2019. PMID: 31578921 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

68 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year